提高肝癌免疫治疗疗效:临床前与临床研究相结合的力量
肝细胞癌缺乏基于机制的有效治疗,免疫检查点抑制剂在未做临床前研究的情况下直接进入晚期肝细胞癌临床试验,显示毒性可控但疗效有限、应答率低。本综述强调动物模型与临床前和临床研究相结合对改善肝细胞癌免疫治疗的价值,并提及阿替利珠单抗联合贝伐珠单抗的3期试验在不可切除肝细胞癌中总生存和无进展生存优于索拉非尼。
要点
- 免疫检查点抑制剂在晚期肝细胞癌中毒性可控但治疗获益有限、应答率低。
- 将「冷」肿瘤转为「热」且应答的肿瘤可能依赖动物模型机制研究与人类大数据分析。
- 3期试验显示阿替利珠单抗联合贝伐珠单抗在不可切除肝细胞癌中总生存和无进展生存优于索拉非尼。
核心结论
- 本综述强调动物模型的价值以及将临床前与临床研究相结合以改善肝细胞癌免疫治疗的效力。
研究设计与样本
- 综述,总结肝细胞癌免疫检查点抑制剂临床研究及临床前与临床研究结合的相关证据。
主要发现
- 免疫检查点抑制剂在晚期肝细胞癌患者中显示毒性可控和安全性,但治疗获益有限,提示应答率低。
- 一项3期临床试验显示,阿替利珠单抗联合贝伐珠单抗在不可切除肝细胞癌中的总生存率和无进展生存率优于索拉非尼。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is a most deadly malignant disease worldwide, with no effective mechanism-based therapy available. Therefore, following the "miracle" outcomes seen in a few patients at the advanced stages of melanoma or lung cancer, the immune checkpoint inhibitors (ICIs) immediately entered clinical trials for advanced HCC patients without pre-clinical studies. Emerging data of clinical studies showed manageable toxicity and safety but limited therapeutic benefit to HCC patients, suggesting low response rate. Thus, one urgent issue is how to convert the liver tumors from cold to hot and responsive, which may rely on in-depth mechanistic studies in animal models and large scale data analysis in human patients. One ongoing approach is to design combinatorial treatment of different ICIs with other reagents and modalities. Indeed, a phase 3 clinical trial showed that combination of atezolizumab and bevacizumab achieved better overall and progression-free survival rates than sorafenib in unresectable HCC. This review highlights the value of animal models and the power of combining pre-clinical and clinical studies in efforts to improve HCC immunotherapy.
引用
- Feng GS, Hanley KL, Liang Y, et al. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology. 2020. PMID: 32715491. doi:10.1002/hep.31479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。